Brief: ArgenX Shows Positive Vyvgart Results In Adapt Seron Study
25/08/2025 06:07
Aug 25 (Reuters) - argenx SE ARGX.BR: ANNOUNCES POSITIVE TOPLINE RESULTS FROM ADAPT SERON STUDY OF VYVGART IN PATIENTS WITH ACHR-AB SERONEGATIVE GMG SBLA TO BE SUBMITTED TO FDA BY END OF 2025 PLANS SBLA SUBMISSION TO EXPAND VYVGART LABEL Source text: ID:nGNE4gBCLW Further company coverage: ARGX.BR (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))